Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102206 · ClinicalTrials.gov registry record · Phase 2
A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00102206: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00102206 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00102206, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment.
Interventions
- DRUG Lamivudine
- DRUG Saquinavir
- DRUG Emtricitabine
- DRUG Abacavir sulfate
- DRUG Lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00102206 record still lists
NCT00102206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00102206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00102206 about?
NCT00102206 is a clinical study titled "A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy". HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcript...
What is the current status of trial NCT00102206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00102206?
The interventions under investigation include: Lamivudine (DRUG), Saquinavir (DRUG), Emtricitabine (DRUG), Abacavir sulfate (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00102206?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00102206's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08